bioAffinity Technologies, Inc. Common Stock
Veridion Score
Composite trend over time
Why is BIAF moving today?
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for BIAF.
BIAF insider activity
bioAffinity Technologies, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for BIAF.
BIAF contract awards, year to date.
Public federal awards linked to this ticker.
BIAF lobbying filings, year to date.
Registered lobbying filings matched to bioAffinity Technologies, Inc. Common Stock.